HCM
ACAD icon

Highlander Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Highlander Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-300
Closed -$13K – 828
2015
Q2 		$13K Buy
+300
New +$11.6K 0.01% 615

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Highlander Capital Management's ACAD Position: Q3 2015 in Review

Highlander Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q3 2015, closing a stake of 300 shares — an estimated $13K sold.

Highlander Capital Management first reported a position in ACAD in Q2 2015 and held it in 1 quarter. The position peaked at $13K in Q2 2015. 188 funds tracked by Wall St. Rank hold ACAD as of Q3 2015.

  • Highlander Capital Management reported no remaining Acadia Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Highlander Capital Management sold 300 Acadia Pharmaceuticals shares in Q3 2015, an estimated $13K.
  • Highlander Capital Management first reported a position in Acadia Pharmaceuticals in Q2 2015 and held it in 1 quarter.
  • Highlander Capital Management's Acadia Pharmaceuticals position peaked at $13K in Q2 2015.
  • 188 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2015.

Based on Highlander Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.